BioSpace News Archive

Addressing the need for increased flexibility, speed and accuracy in research applications throughout academic and industry laboratories, a new gas chromatography (GC) high-resolution mass spectrometer (MS) with unrivalled mass resolving power, sensitivity and wide dynamic range offers researchers the capability to achieve new depths of analysis and drive scientific understanding

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced it has entered into a clinical development collaboration with AgonOx, Inc.

Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biopharmaceutical company developing innovative medicines to improve the lives of patients with cancer and inflammatory diseases, announced an oral presentation at the 2021 NASH-TAG Conference held virtually on March 11-13, 2021 .

February marked the celebration of No One Eats Alone Day, a nationwide initiative created by Beyond DifferencesTM, to promote inclusion among children and address social isolation.

In honor of National Kidney Month which starts today, the National Kidney Foundation’s (NKF) national public awareness campaign, “Are You the 33%?” enters a new phase focusing on the connection between type 2 diabetes (T2D) and kidney disease, also known as chronic kidney disease (CKD).

Maine’s Largest Statewide Physician-Owned Multispecialty Adopts Integrated Ambulatory Platform to Improve Patient-Provider Experience and Financial Outcomes

Vetex Medical Ltd. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the ReVene® Thrombectomy Catheter. ReVene uses dual-action technology designed to de-clot peripheral vessels, such as in Deep Vein Thrombosis (DVT), through wall-to-wall contact in a single session without the use of thrombolytics.

PanTheryx Inc. Acquires TruBiotics ® Brand from Bayer HealthCare LLC Acquisition Expands PanTheryx’s Digestive and Immune Health Product Lines for Human Nutrition

The T-cell therapy market is anticipated to rise at a stellar growth rate for the forecast period between 2020 and 2030.

BioInvent International AB and Transgene announced that the first patient in a Phase I/IIa clinical trial of the novel dual mechanism-of-action oncolytic vaccinia virus BT-001 has been enrolled at Institut Bergonié.